How We Help
SHEPHERD is Filling the Rare Cancer Development Gap
Our platform agnostic approach means that we develop the best molecule for an individual indication. And by putting AI and big data to work, we’re able to deploy and apply vast amounts of information across a broad range of cancers. Learn more about our development approach.